Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostate
Interventions: Internet-Based Intervention; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more

Conditions: Prostate Cancer
Interventions: PSMA-PET and SOC MRI, SOC MRI; Diagnostic Test
Lead sponsor: Five Eleven Pharma, Inc.; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions: Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 50 more

Conditions: Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
Interventions: Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 69
States / cities: Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more

Conditions: Prostate Cancers
Interventions: anti [18F]FACBC; Drug
Lead sponsor: David M. Schuster, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Decitabine and Cedazuridine, Enzalutamide; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 2,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer Recurrent, Prostate Cancer
Interventions: Ga-68 P16-093 PET/CT scan; Drug
Lead sponsor: Five Eleven Pharma, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Male Erectile Disorder, Prostate Cancer, Radiation Toxicity
Interventions: Placebo, Oral L-Arginine; Other · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Adenocarcinoma of the Prostate
Interventions: Stereotactic Radiosurgical Boost, Casodex, Leuprolide; Radiation · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Cancer, Hot Flashes
Interventions: .5% Bupivacaine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glioblastoma
Interventions: 89Zr-J591, PET/CT Scan, MRI, Blood draw; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 26 Years to 79 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: avodart, Placebo; Drug
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 35 Years to 90 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Prostate Cancer
Interventions: green tea extract; Dietary Supplement
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 16
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 13 more

Conditions: Prostate Cancer
Interventions: Educational intervention.; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Prostatic Neoplasms, Neoplasm Metastasis
Interventions: Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Breast Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Gastric Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Prostate Carcinoma
Interventions: Interview, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma, Chronic Lymphocytic Leukemia, Neoplasm Metastasis
Interventions: CC-115; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more

Conditions: Opioid Consumption, Postoperative, Multimodal Analgesia, Robotic Assisted Laparoscopic Surgery, Robotic Assisted Laparoscopic Radical Prostatectomy, Prostate Cancer
Interventions: multimodal analgesia pathway with up-front small opioid prescription, multimodal analgesia pathway without up-front small opioid prescription, pre-implementation baseline including opioid; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Cancers of the Prostate, Cancers of the Lung
Interventions: Multilevel intervention; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 2,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Prostate Neoplasms
Interventions: Leuprolide or goserelin, Transdermal estradiol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Seattle, Washington

Search by objective public record fields.

Electronic Patient Reported Outcomes in Measuring Health-Related Quality of Life in Patients With Stage I-IV Prostate Cancer Undergoing Treatment

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

PSMA-PET to Guide Prostatectomy

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

Green Tea Extract in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Improving Germline Testing in At-Risk Patients With Prostate Cancer

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

Health-Related Quality of Life in Gay Men With Localized Prostate Cancer

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

Multilevel Intervention for Precision Oncology

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer